期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

miR-34a在结直肠癌中的表达及其临床意义 被引量：6

Expression of miR-34a and its clinical significance in human colorectal carcinoma
下载PDF
导出
摘要 目的探讨miR-34a在结直肠癌中的表达及其与临床病理特征的关系。方法应用实时荧光定量PCR法对43例结直肠癌及其癌旁正常组织中miR-34a进行定量检测。结果结直肠癌组织中miR-34a表达水平明显高于癌旁正常组织,差异有统计学意义(P>0.05);miR-34a在结直肠癌组织中的表达与患者性别、年龄、肿瘤部位、肿块大小、淋巴结转移均无相关性(P>0.05),而与浸润深度、TNM分期密切相关(P<0.05)。结论 miR-34a在结直肠癌的发生、发展过程可能发挥重要作用,检测miR-34a有望成为结直肠癌新的肿瘤标记物或预后因子。 Purpose To investigate the expression of miR-34a in human colorectal carcinoma and its relationship with clinicopathological features.Methods The mRNA expression of miR-34a was determined by real-time quantitative PCR in 43 colorectal carcinoma tissues and para-cancerous normal tissues.Results Real-time quantitative PCR analysis revealed that miR-34a expression in colorectal carcinoma tissues was lower than those in the paraneoplastic colorectal tissues（P0.05）.There were no significant correlations between the expression of miR-34a and gender,age,tumor location,tumor size and lymph node metastases（P0.05）,but it related to depth of invasion and TNM stage（P0.05）.Conclusions Downregulation of miR-34a expression in the colorectal carcinoma suggests that miR-34a may be involved in the carcinogenesis and development of colorectal carcinoma.miR-34a may be a novel useful tumor marker and a prognostic factor for colorectal carcinoma.
作者 田智丹 任勇亚 戚晓红 冯振卿
机构地区 南京医科大学附属南京第一医院病理科 南京医科大学病理学与病理生理学系
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2011年第4期347-350,共4页 Chinese Journal of Clinical and Experimental Pathology
关键词 结直肠肿瘤 MIR-34A 实时荧光定量PCR colorectal neoplasms miR-34a real-time quantitative PCR
分类号 R735.3 [医药卫生—肿瘤]
  • 相关文献

参考文献21

  • 1He L,Hannon G J.MicroRNAs:small RNAs with a big role in gene regulation[J].Nat Rev Genet,2004,5(7):522-31.
  • 2Shyu A B,Wilkinson M F,van Hoof A.Messenger RNA regulation:to translate or to degrade[J].EMBO J,2008,27(3):471-8.
  • 3Neely L A,Patel S,Garver J,et al.A single-molecule method for the quantitation of microRNA gene expression[J].Nat Methods,2006,3(1):41-6.
  • 4Berezikov E,Cuppen E,Plasterk R H.Approaches to microRNA discovery[J].Nat Genet,2006,38S:2-7.
  • 5Lin S L,Chang S J,Ying S Y.First in vivo evidence of microRNA-induced fragile X mental retardation syndrome[J].Mol Psychiatr,2006,11(7):616-7.
  • 6Van Rooij E,Sutherland L B,Liu N,et al.A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heat failure[J].Proc Natl Acad Sci USA,2006,103(48):18255-60.
  • 7Calin G A,Croce C M.MicroRNA-cancer connection:the beginning of a new tale[J].Cancer Res,2006,66(15):7390-4.
  • 8Iwai N,Naraba H.Polymorphisms in human pre-miRNAs[J].Biochem Biophys Res Commun,2005,331(4):1439-44.
  • 9Yoriaki S,Takehiko K,Takashi Y,et al.The incidence of apoptosis during colorectal tumorigenesis[J].Int J Surg Pathol,2000,8(2):123-32.
  • 10Chang W C,Chapkin R S,Lupton J R.Predictive value of proliferation,differentiation and apoptosis as intermediate markers for colon tumorigenesis[J].Carcinogenesis,1997,18(4):721-30.

二级参考文献7

  • 1[1]Garewal H, Bernstein N, Bernstein C, et al. Reduced bile acid-induced apoptosis in "normal" colorectal mucosa: a potential biological marker for cancer risk. Cancer Res, 1996,56:1480～3.
  • 2全国结直肠癌病理研究协作组.全国结直肠癌病理研究统一规范[J].中华肿瘤杂志,1986,(8):156.
  • 3[3]Bosari S, Moneghini L, Graziani D, et al. Bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol, 1995,26:534～40.
  • 4[4]Manne U, Myers RB, Moran C, et al. Prognostic aignificance of bcl-2 expression and p53 nuclear accumulation in colorectal adenocarcinoma. Int J Cancer, 1997,74:346～58.
  • 5[5]Mosnier JF, Perret AG, Vindimian M, et al. An immunohistochemical study of the simultaneous expression of bcl-2 and p53 oncoproteins in epithelial tumor of the colon and rectum. Arch Pathol Lab Med, 1996,120:654.
  • 6[6]Sinicrope FA, Ruan SB, Cleary KR, et al. Bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res, 1995,55:237～41.
  • 7[7]Silvestrini R, Veneron S, Daidone GE, et al. The bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node negative breast cancer patients. J Nat Cancer Inst, 1994,86:499～504.

共引文献2

同被引文献60

  • 1Yutaka Midorikawa,Masatoshi Makuuchi,Wei Tang,Hiroyuki Aburatani.Microarray-based analysis for hepatocellular carcinoma: From gene expression profiling to new challenges[J].World Journal of Gastroenterology,2007,13(10):1487-1492. 被引量：5
  • 2BERTOS NR, PARK M. Breast cancer-one term, many entities[J]. Clin Invest, 2011, 121(10): 3789-3796.
  • 3VODUC KD, CHEANG MC, TYLDESLEY S, el al. Breast can- cer subtypes and the risk of local and regional relapse[J]. Clin Oncol, 2010, 28(10): 1684-1691.
  • 4LEE DS, KIM SH, SUH YJ, et al. Clinical implication of p53 overexplvssion in breast cancer patients younger than 50 years with a triple-negative subtype who undergo a modified radical mastectomy[J]. Jim J Clin Oncnl, 2011, 41(7): 854-866.
  • 5CURIGLIANO G, GOLDHIRSCH A. The triple-negative subtype: new ideas few the poorest prognosis breast cancer[J]. Natl Cancer Inst Monogr, 2011, 43: 108-110.
  • 6FORNIER M, FUMOLEAU P. The paradox of triple negative breast cancer: novel approaches to trealment [J ]. Breast J, 2012, 18(11): 41-51.
  • 7IRSHAD S, ELl,IS P, TUTT A. Molecular heterogeneity of triple-negative breast cancer and its clinical implications[J]. Curr Opin Oncol, 2011, 23(6): 566-577.
  • 8GLUZ O, LIEDTKE C, GOTFSCHALK N, et al. Triple-negative breast eancer-current status and future directions[JI. Ann Oncol, 2009, 20(12): 1913-1927.
  • 9GARCIA AI, BUISSON M, BERTRAND P. et al. Down-regula- tion of BRCAI expression by miR-146a and miR146b-Sp in triple negative sporadic breast cancers[J]. EMBO Mnl Med, 2011, 3(5): 279-290.
  • 10RADOJICIC J, ZARAVINOS A, VREKOUSSIS T, et al. MicmR- N A expression analysis in triple-negative (ER, PR and Her2/ne,a) breast cancer[J]. Cell Cycle, 2011, 10(3): 507-517.

引证文献6

二级引证文献19

临床与实验病理学杂志
2011年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部